The preferred stock financing round was led by Illumina Ventures, with participation by all of the company's current major investors. RedShiftBio said it would use the proceeds to fund additional commercial expansion and develop new applications and products.

The firm is developing platform technology to enable the measurement of previously undetectable structure changes in biomolecules.